Inter-Pharma Express Inc.
|JAPANESE・ ENGLISH ・|
TEL&FAX +81 3 3586 3317
N e w s
105. Marketing research on pharmaceutical construction project in Singapore based on Japanese engineering/construction company in July 2018
104. Hold the seminar explainig the concept, origine and history of G seiries (GCP, GLP and GMP) in June 2018
103. Implementing the contractor(German) audit for anticancer drug development for Japanese pharmaceutical development company in June 2018
102. Consultation on the reliability scheme and GLP compliance of domestic bio venture in March 2018(ongoing)>
101. Consultation on the reliability scheme and GLP compliance of domestic bio venture in December 2017(ongoing)
100. Implemnt GMP consultation for manufacturing subcontractor of Bio venture established by Japanese Pharmaceutical commpany in October 2017
99. Implement consultation and support work for formulation development and CMC work of inhalation drug for University-launched venture company in October 2017
98. Implement consultation and mock audit to API facilities in April 2017
97. Consultation on the reliability scheme and GLP compliance of domestic bio venture in January 2017(ongoing)
96. Join establishmentd team for Long-term listed drugs manufacture and sale in January 2017 and accomplish chaireman duty
95. Hold the seminar for pharmaceutical related sector of the University about GMP concept in October 2016
94. Decontamination consultation for Hormone manufacturing facility in January 2016.
93. Consultation on the reliability scheme and GLP compliance of domestic bio venture in December 2015.
92. Consultation for medical equipment of Class IV in October 2015.
91. Investigation on the regulatory of track & trace system for Indian market in October 2015.
90. Investigation on domestic market for bio-similar in September 2015.
89. Investigation for import procedure for pharmaceutical purpose Gelatin in August 2015.
88. Marketing consultation of aseptic sampling system for foreign manufacturer in July 2015.
87. Soil conditioner export consultation for domestic company in July 2015.
86. Investigation for domestic scheme of HIP and reimbursement systems in July 2015.
85. Marketing research on transdermal patch preparation in US market in June 2015.
84. Investigation on new drug and generics submission to FDA in May 2015.
83. ANDA(FDA) related judicial action survey for domestic company in April 2015.
82. Project management consultation for new pharmaceutical facility for domestic company in April 2015.
81. GMP Training for domestic pharmaceutical company in April 2015.
80. Investigation of the DMF registration processes to FDA in April 2015.
79. Marketing research of domestic CROs and CMOs in April 2015.
78. Support for the submission of medical equipment class II and III in March 2015.
77. QSR Gap analysis and prepare the corrective action in January 2015.
76. Business development support & partnering search for overseas bio industry in January 2015.
75. Implement consultation and mock audit to foreign pharmaceutcal company for API facilities based on Japanease client point of view, in August 2014.
74. Implement project management consultation to domestic pharmaceutcal company for new API project, in May 2014.
73. Implement support and consultation work to domestic pharmaceutical company for developing new formulation, in April 2014.
72. Implement support and consultation work to European pharmaceutical company for EMA base auditing the Japanese Bio API manufacturer, in April 2014.
71. Implement consultation and support work to foreign pharmaceutical company for investigating the regulatory change control issue in Japan, in April 2014.
70. Implement consultation and support work to foreign pharmaceutial company for NDA in Japan, in March 2014.
69. Support for FDA submission of domestic pharmaceutical company for NDA, in February 2014.
68. Conduct HAZOP study to domestic pharmaceutcal company for new API project risk assessment, in January 2014.
67. Support for IND submission of overseas bio industry and contract agent as PMDA submission, in December 2013.
66. Implement project management consultation to domestic pharmaceutcal company for new API project, in December 2013.
65. Implement support work to European pharmaceutical company for auditing the Japanese Bio API manufacturer, in October 2013.
64. Implement investigation of CMOs business in terms of business development and company assessment.
63. Implement consultation and support work to chemical company for deveolpping new businessfield of API, in October 2013.
62. Implement consultation work to foreign pharmaceutical compnay Japan affiliate for reviewing/auditing quality related documentation, in October 2013.
61. Implement consultation work to domestic pharmaceutical compnay for developing transdermal medicine US market, in April 2013.
60. Implement consultation and audit work to overseas pharmaceutical manufacturer for domestic CRO in March, 2013.
59. Implement consultation and support work to the image processing device manufacturer for developing the pharmaceutical industries market, in December 2012.
58. Implemented a consultation to an overseas pharmaceutical manufacturer, for evaluation and selection of a Japanese CMO in June, 2011.
57. Implement consultation and support work to two Japanese dietary supplement manufacturers for FDA inspection in October/November 2012.
56. Implement consultation and support work to Japanese pharmaceutical company for contracting with CRO in UK in September 2012.
55. Implement investigation to overseas manufacturer for current DMF system in Japan, Korea and China in August 2012.
54. Implement Medical Device GMP GAP Analysis for Chinese manufacturer in China in July 2012.
53. Business Alliance agreement with Debiopharm SA, CH, in July, 2012.
52. BIHOLON, dietary supplement manufacturer in Japan, obtained renewal certification from USA NPA GMP in April, 2012.
51. Implement a consultation to domestic manufacturer for obtaining the EU CEP certificate in March 2012.
50. Implement a consultation to overseas pharmaceutical manufacturer for domestic authorities regulatory requirements for various changes in January, 2012.
49. Implement GMP GAP Analysis for trans dermal adhesive skin patch manufacturers in Japan in December, 2011.
48. Implemented a GMP GAP Analysis for an API manufacturer in Japan in July, 2011.
47. Implemented a consultation to an overseas pharmaceutical manufacturer, for evaluation and selection of a Japanese CMO in June, 2011.
46. Implemented a consultation to an Overseas dietary supplement producer, to develop the Japanese market. in May, 2011.
45. Implemented a consultation to an Overseas pharmaceutical company to support PMDA application. in May, 2011.
44. An Overseas pharmaceutical company executed a world-wide survey for change control procedures. IPE was assigned to investigate the Japanese regulatory agent portion, in April 2011.
43. Implemented a consultation to a Japanese adhesive skin patch manufacturer for developing the overseas market, in April, 2011.
42. Business Alliance agreement with TRB CHEMEDICA INTERNATIONAL S.A.(CH),in December, 2010.
41. Registered in Swiss Business Hub (Embassy of Switzerland) in December, 2010.
40. Business Alliance agreement with EuroConsult, Inc (USA) in October, 2010 and implemented due diligence.
39. Business Alliance agreement with Pharmalink Consulting, Inc. (USA) in October, 2010.
38. Business Alliance agreement with RBQ Services Limited(UK) in June, 2010.
37. Implemented a consultation to a Japanese API manufacturer for EDQM inspection in May, 2010.
36. Assisted BIHOLON, a dietary supplement manufacturer in Japan, in obtaining renewal certification with respect to USA NPA GMP in April, 2010.
35. Business Alliance agreement with Anthem Biosciences Pvt .Ltd.(India) in April, 2010.
34. Management consultant to Japanese in vitro diagnostic manufacturer for overseas business in December, 2009.
33. Assisted a Japanese pharmaceutical company for subcontracting their clinical drug manufacturing to Quay Pharmaceuticals in the UK in October, 2009.
32. Implemented a consultation to develop a medical device for a Japanese device manufacturer in September, 2009.
31. Implemented a consultation to an overseas excipient manufacturer for DMF (PMDA) submission in August, 2009.
30. Implemented a consultation to a Japanese API manufacturer for FDA PMA in July, 2009.
29. Implemented a European Regulatory survey for APIs to a Japanese Chemical Company in May, 2009.
28. Implemented an imaging study at Bio-Images Research Ltd. UK in May, 2009.
27. Implemented a consultation for a pharmaceutical equipment QMS. in April, 2009.
26. Implemented GMP GAP Analysis for the Dietary Supplement industry in Japan in March, 2009.
25. Project management consultation for a new investment plan for an Irish- Japanese pharmaceutical company in March, 2009.
24. Obtained additional two contracts for regulatory and translation consultancy with a multinational in the pharmaceutical industry in January, 2009.
23. Export Market research and consultation for a domestic pharmaceutical manufacturer, specialized in DDS in October, 2008.
22. Consultation for submitting the Drug Master File to overseas regulatory authorities in July, 2008.
21. FDA GMP GAP Analysis consultation for an R&D Type domestic pharmaceutical manufacturer in May, 2008.
20. Client “BIHOLON”, a dietary supplement manufacturer in Japan, gained certification by USA NPA GMP based on a one year effort supported by IPE.
19. Business Alliance agreement with BioPoint (Korean firm of pharmaceutical consultants) and Pacific Medical (USA medical device firm) in April, 2008.
18. Gained a Consultancy Agreement with a Japanese CRO/CMO in January, 2008.
17. Project Management Consultant for a Japanese major pharmaceutical company's new domestic investment large scale project in October, 2007.
16. Started NDA consultancy to TEVA Japan KK in June, 2007.
15. Started a business alliance with TCI (US) in May, 2007.
14. Started business development consultancy to MED Discovery Ltd (CH) in April, 2007.
13. Started a sales and marketing consultancy to ACG group (India) in February, 2007.
12. Provided GMP documents development and validation support service to Japanese clinical pharmaceutical facilities in February, 2007.
11. Provided NPA(USA) GMP certification program consultancy services to Japanese dietary supplement manufacturer in February, 2007.
10. Provided anti-biotic production facilities decontamination consultancy services to a Japanese pharmaceutical company in November, 2006.
9. Started an overseas business consultancy service to a Japanese DDS Company in October, 2006.
8. Started healthcare equipment regulatory consultancy services to a Medical Device Manufacturer in September, 2006.
7. Provided project management consultancy services to a Japanese clinical pharmaceutical business in September, 2006.
6. Formulated a contract between Quay Pharmaceuticals in the UK and a Japanese pharmaceutical company in April, 2006.
5. Formulated a contract between Bio-Images Labo in the UK and a Japanese pharmaceutical company in April, 2006.
4. Provided project management consultancy services for overseas presence of a Japanese pharmaceutical company in March, 2006.
3. Provided project management consultancy services for overseas presence of a Japanese pharmaceutical company in January, 2006.
2. Started a business alliance with Bio-Images Laboratories in November, 2005.
1. Started a business alliance with Quay Pharmaceuticals in April, 2005.